Cutaneous Lupus Erythematosus (CLE) Epidemiology Forecast

Cutaneous Lupus Erythematosus (CLE) Insights and Trends

• According to Delveinsight’s amalysis, the diagnosed prevalent cases of CLE in the 7MM were ~793,000 in 2025, rising at a CAGR of 2.2% during the study period (2025–2036); these are expected to increase by 2036. Increasing disease awareness, improved diagnostic capabilities, better access to specialist care, enhanced recognition of diverse CLE manifestations, and its chronic relapsing nature are driving the growth in diagnosed prevalent cases.
• CLE occurs in up to 85% of patients with Systemic Lupus Erythematous (SLE) and is the initial manifestation in approximately 29%, making dermatologists key players in early detection, risk stratification, and co-management.
• The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) becomes the accepted primary endpoint in clinical trials, drug development is increasingly focusing on skin-specific outcomes.
• Underdiagnosis and misdiagnosis of CLE with other dermatological conditions contribute to delayed diagnosis and inappropriate treatment, while improving disease awareness and diagnostic accuracy are increasing the identification of cases.
• Advances in understanding the molecular mechanisms underlying CLE have identified type I interferon signaling as a central driver of disease pathology. This has led to a shift in therapeutic development toward targeted immunomodulatory approaches designed to interrupt key inflammatory pathways while minimizing systemic toxicity. A precise, Japan-wide percentage breakdown for each CLE subtype is not well established in the sources surfaced here, and the available Japanese literature is more qualitative than registrybased for subtype prevalence. Therefore, the subtype distribution in Japan appears skewed toward CCLE/DLE, with SCLE and ACLE less common.

Cutaneous Lupus Erythematosus (CLE) Epidemiology Forecast in the 7MM

• 2025 Prevalent Cases of CLE: ~793,000
• 2036 Projected Prevalent Cases of CLE: ~XXX
• CLE Growth Rate (2026–2036): ~2.2% CAGR

DelveInsight's ‘Cutaneous Lupus Erythematosus (CLE) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the CLE, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Cutaneous Lupus Erythematosus (CLE) Understanding and Diagnosis Algorithm

Cutaneous Lupus Erythematosus (CLE) Overview

CLE is a chronic autoimmune inflammatory skin disorder characterized by immune-mediated damage to the skin, resulting in photosensitive lesions that may lead to scarring, dyspigmentation, and permanent alopecia depending on the disease subtype. CLE encompasses a spectrum of clinical presentations, including acute (ACLE), subacute (SCLE), and chronic forms (CCLE), with Discoid Lupus Erythematosus (DLE) being the most common chronic subtype. While some patients have disease confined to the skin, others may develop or coexist with SLE. The pathogenesis involves a complex interplay of genetic susceptibility, ultraviolet (UV) radiation, environmental triggers, and immune dysregulation, particularly activation of type I interferon signaling, autoreactive T and B lymphocytes, and pro-inflammatory cytokines. CLE significantly impacts patients' quality of life owing to visible skin lesions, chronic disease course, pain, pruritus, and psychosocial distress.

Further details are provided in the report.

Cutaneous Lupus Erythematosus (CLE) Diagnosis

The diagnosis of CLE is based on a combination of clinical evaluation, histopathological examination, and laboratory investigations. Dermatological assessment focuses on lesion morphology, distribution, photosensitivity, and evidence of scarring or pigmentary changes. Confirmation is typically obtained through skin biopsy, which demonstrates interface dermatitis and other characteristic histological features, while direct immunofluorescence may reveal immunoglobulin and complement deposition at the dermoepidermal junction. Laboratory investigations include antinuclear antibody (ANA) testing, anti-double-stranded DNA antibodies, anti-Ro/SSA and anti-La/SSB antibodies, complement levels, and other autoimmune markers to evaluate systemic involvement. Disease severity and treatment response are commonly monitored using validated scoring tools such as the CLASI, while patients are periodically assessed for progression to systemic lupus.

Further details are provided in the report.

Cutaneous Lupus Erythematosus (CLE) Epidemiology

Key Findings from Cutaneous Lupus Erythematosus (CLE) Epidemiological Analysis and Forecast

• Among the 7MM, the US accounted for the highest number of cases of CLE in 2025, with ~390,500 cases. These cases are anticipated to increase by 2036.
• According to DelveInsight’s analysis, the total treated cases of CLE by line of therapy were highest in first line in US in 2025 with ~273,400 cases.
• Among the EU4 and the UK, Spain (~30%) accounted for the highest diagnosed prevalent cases of CLE in 2025 followed by UK. The lowest number of cases were seen in Italy. 
• In the United States, among the type-specific cases of CLE reported in 2025, CCLE had the highest number, with ~247,600 cases followed by SCLE. 
• In Spain, among the severity-specific cases, mild (~55) accounted for the highest number of cases followed by moderate and severe in 2025.
• Across the 7MM, the gender-specific distribution of CLE cases was higher among females than males in 2025.

Scope of the Report

• The report covers a segment of a descriptive overview of CLE, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Cutaneous Lupus Erythematosus (CLE) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by Geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Cutaneous Lupus Erythematosus (CLE)? What will be the growth opportunities across the 7MM concerning the patient population with Cutaneous Lupus Erythematosus (CLE)?
• What is the historical and forecasted Cutaneous Lupus Erythematosus (CLE) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.